Top Ibuprofen Brands: Relieving Pain with Trusted Quality

Choosing the right brand of ibuprofen can make a significant difference in how effectively you manage pain. With numerous options available, consumers often seek out names they can trust for quality, efficacy, and safety. This article aims to provide you with a comprehensive list of the best brands for ibuprofen that have consistently received positive feedback from users and healthcare professionals alike. Whether you're looking for over-the-counter solutions or recommendations for specific needs, read on to discover which brands might best serve your requirements.

Illustration of ibuprofen

Best brands of ibuprofen in 2025

Advil

Advil, a prominent brand of ibuprofen, is widely recognized for its effectiveness in alleviating pain, fever, and inflammation. As one of the most commonly used NSAIDs, Advil holds a significant market share, with the global ibuprofen market expected to grow at a CAGR of 7.8% from 2024 to 2033, reaching approximately USD 205.6 million by 2033. In 2023, the tablet segment, which includes Advil, dominated the market with over 41.6% share, driven by its ease of use and widespread availability. North America, where Advil is heavily marketed, captured more than 40% of the global revenue in 2024, with a market size of USD 48.64 million. Advil's efficacy and broad distribution network contribute significantly to its market leadership.

Motrin

Motrin, a renowned brand, is a leading producer of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce fever, and alleviate inflammation. In 2024, the global ibuprofen market, which includes Motrin products, was valued at USD 121.6 million, with North America holding over 40% of the global revenue, driven partly by Motrin's widespread use. Motrin products, such as Adult MOTRIN(r) IB and Children's MOTRIN(r), contain 200 milligrams of ibuprofen and are available in various forms like tablets and Liquid Gels. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 8.5% from 2024 to 2031, reflecting the ongoing demand for effective pain management solutions like Motrin. Motrin's efficacy in treating minor aches, headaches, and menstrual cramps has solidified its position as a trusted brand in the ibuprofen market. For more information, visit Motrin's website.

Nurofen

Nurofen, a prominent brand of ibuprofen, is recognized for its effective pain relief and anti-inflammatory properties. As an active ingredient in Nurofen, ibuprofen is widely used to alleviate pain, fever, and inflammation, with formulations like Nurofen Quickzorb and Nurofen Zavance offering rapid absorption. In 2023, the ibuprofen market, which includes Nurofen, saw significant growth, with the tablet segment holding over 41.6% of the market share. Nurofen's products are designed for various age groups, including children's liquid formulations and soft chewable capsules. The brand's efficacy and diverse formulations contribute to its popularity in managing conditions like rheumatoid arthritis and osteoarthritis.

Brufen

Brufen, a prominent brand of ibuprofen, was first marketed in 1969 in the United Kingdom and later in 1974 in the United States, marking a significant milestone in the treatment of rheumatoid arthritis and other inflammatory conditions. Developed by the Boots Group, Brufen is known for its efficacy and safety, contributing to its widespread use. The ibuprofen market, which includes Brufen, is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.8% to 8.5% from 2024 to 2033, reaching a market size of approximately USD 205.6 million to USD 213.6 million by 2033. Brufen's success is also reflected in its market share, with tablets, such as those under the Brufen brand, holding over 41.6% of the market share in 2023. The brand's popularity is further underscored by its inclusion in the World Health Organization's List of Essential Medicines. For more detailed insights about ibuprofen, you can visit the Wikipedia page on Ibuprofen.

Genpril

Genpril, a brand of ibuprofen, is recognized for its high bioavailability and improved curative effects, particularly notable in comparison to other domestic productions. The tablets are manufactured with a principal agent granularity of 0.5-1 mm, significantly finer than some domestic counterparts, enhancing absorption and efficacy. Genpril is part of the ibuprofen market, which is projected to grow at a CAGR of 7.8% from 2023 to 2033, reaching a market size of approximately USD 205.6 million by 2033. Tablets, such as those produced by Genpril, dominate the market with a 41.6% share in 2023. The brand's formulation includes additives like starch, hydroxypropyl cellulose, and gelatinized corn starch to optimize its performance.

Midol

Midol, while not exclusively an ibuprofen brand, is renowned for its multi-symptom relief products that often include ibuprofen or other pain relievers. Midol Complete, for example, provides up to six hours of relief from period symptoms such as cramps, bloating, and headaches, making it a popular choice for menstrual pain management. Although Midol products may not be pure ibuprofen, they leverage the efficacy of ibuprofen and other active ingredients like acetaminophen, caffeine, and pyrilamine maleate to offer comprehensive relief. Midol's formulations are designed for ease of use, available in caplets or gelcaps, and are recommended for both adults and children 12 years or older. This versatility and effectiveness contribute to Midol's strong market presence in the pain relief sector.

NeoProfen

NeoProfen, produced by Farmacon-IL, LLC, is a leading brand for ibuprofen lysine, specifically designed to close clinically significant patent ductus arteriosus (PDA) in premature infants. Approved by the FDA on April 13, 2006, NeoProfen has shown efficacy in reducing the need for rescue therapy, with only 25% of infants requiring it compared to 48% on placebo. The drug is administered intravenously, with a dosing regimen of 10 mg/kg followed by 5 mg/kg at 24 and 48 hours. It is available in 2 mL single-use vials, each containing 17.1 mg of ibuprofen lysine per mL. NeoProfen's pharmacokinetics indicate a clearance rate that increases rapidly with post-natal age, making it a reliable treatment option. For more information, visit the NeoProfen FDA approval history page.

Profen

Profen, a notable brand in the ibuprofen market, is recognized for its high-quality ibuprofen products, which are widely used to treat mild to moderate pain, fever, and inflammation. The ibuprofen market, where Profen operates, is projected to grow at a CAGR of 2.40% from 2024 to 2031, reaching USD 111.41 million by 2031. In 2023, the tablet segment, which includes Profen's products, held a substantial market share of over 41.6% due to its ease of use and wide applications. Profen's products are part of a market driven by increasing chronic pain conditions and a growing aging population. The brand's presence in regions like North America, which accounts for the largest revenue share, further solidifies its position in the market.

Actiprofen

Actiprofen, a leading brand in the ibuprofen market, stands out for its high-quality formulations and significant market presence. In 2024, the global ibuprofen market, which includes brands like Actiprofen, was valued at USD 121.6 million and is expected to grow at a CAGR of 8.50% from 2024 to 2031. North America, a key region for Actiprofen, held over 40% of the global revenue, with a market size of USD 48.64 million in 2024. The brand's commitment to innovation and compliance with stringent regulatory standards has contributed to its market success. Actiprofen's products are widely used for pain relief, fever reduction, and inflammation, catering to a growing demand driven by increasing chronic pain conditions. For more detailed insights, you can view the ibuprofen market report.

Act-3

The global ibuprofen market is dominated by several key players, with no specific mention of Act-3 as a producer in the provided sources. The market size was valued at USD 1.43 billion in 2023 and is projected to reach USD 1.76 billion by 2032, growing at a CAGR of 2.44% during the forecast period. Notable regions such as North America, Europe, and Asia-Pacific drive the demand, with North America holding a substantial share of global revenue. Ibuprofen's widespread use is attributed to its effectiveness in relieving pain, fever, and inflammation, making it a staple in the pharmaceutical industry. For a detailed analysis of the ibuprofen market, you can visit Cognitive Market Research.